Data acquisition (sometimes), standards, and expert curation (often) remain major bottlenecks. Applying AI earlier in the pipeline could help, but trust in the reliability of current models is still limited.

The non-profit sector is showing increasingly sophisticated AI applications, though imho it’s still not fully leveraging its accumulated data and expertise.

But the real flavor comes from the cooks - their domain expertise and data/coding/stats/ML-AI wizardry.

Startups and established biopharma are doubling down on proprietary or federated client data as their “secret sauce.”

Major players like AWS, Microsoft, and NVIDIA are building increasingly comprehensive ecosystems for model access, agent orchestration, and beyond.

Industry had a strong presence, highlighting how AI is reshaping bioinformatics, drug design, and even broader research and software development.

👋